The only FDA-approved peptide for sexual health. Works centrally on desire.
PT-141 (bremelanotide) is a melanocortin-receptor agonist that works on the brain rather than the bloodstream. Unlike Viagra-type drugs that act on blood flow, PT-141 acts centrally on the pathways that govern sexual desire itself.
It is the active ingredient in Vyleesi, which is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the very few peptides on this list with full regulatory approval for a sexual-health indication.
Because it works on desire centrally, it can help where blood-flow drugs fall short, and it is used by both men and women. The trade-off is side effects like nausea and transient flushing, plus a temporary rise in blood pressure.
Increases sexual desire by acting centrally on melanocortin pathways.
FDA-approved (Vyleesi) for HSDD in premenopausal women
Can help erections via central pathways, including some non-responders to PDE5 inhibitors.
Clinical-trial evidence; works differently from blood-flow drugs
Improves desire and arousal-related distress in women with HSDD.
Pivotal trials supported the Vyleesi approval
We rate every peptide honestly across four dimensions — and tell you what it's not.
Evidence Profile
The active compound (bremelanotide) is FDA-approved for HSDD in premenopausal women, backed by controlled human trials.
Backed by human clinical data — one or more controlled human trials show a consistent effect.
Controlled trials & clinical data in people
FDA-approved (Vyleesi) with phase-3 RCT data for female HSDD.
Preclinical results in animal models
Melanocortin pathway effects on sexual behavior shown in animals.
How plausibly it works at a biological level
Central melanocortin-receptor agonism is well established.
Depth of documented safety in humans
Known side effects (nausea, transient BP changes) documented in trials.
Men whose libido or response is low, including some who don't respond fully to PDE5 inhibitors
Dosed on-demand before activity (subcutaneous or intranasal). Expect possible nausea and flushing. Caution with high blood pressure.
Premenopausal women with low sexual desire (HSDD) causing distress
The peptide with the strongest female sexual-health evidence (approved as Vyleesi). Nausea is the most common effect. Not for use in pregnancy.
This section is always free and never locked.
The effects most commonly reported with PT-141, when they tend to show up, and how to manage them.
Lower the dose; it often lessens with use.
Hydrate; usually short-lived.
Caution with blood-pressure meds/nitrates — check with your doctor.
Individual responses vary. Stop and consult a clinician for severe, persistent, or unexpected reactions.
14 steps with photos, pro tips, and a dosing calculator.
Unlock Full Guide7 days free. Then $24/month.
████████ ████
████████ ████
████████ ████
Dosing info requires Core or Pro
Unlock DosingA preview of the member outcomes dashboard. Real, anonymized PT-141 results populate here as the community logs data.
See aggregated results from real users — benefit ratings, common goals, side effect frequency, and more.
Unlock with Core or ProGet the complete step-by-step guide, personalized dosing, and daily tracking.
View Full GuidePepCompass provides educational information only. Nothing on this platform constitutes medical advice, diagnosis, or treatment. All content is for informational and research purposes only. Always consult a licensed healthcare provider before starting any peptide protocol. Individual results vary.